Dr. Hanan Sayed Anbar Discusses Promising Drug Candidates for Polycystic Ovary Syndrome (PCOS) at Gulf Medical University Research Seminar

On Thursday, September 19th, the College of Pharmacy at Gulf Medical University hosted a joint research seminar delivered by Dr. Hanan Sayed Anbar, Associate Professor and Head of the BPharm Research and Ethical Committee at Dubai Pharmacy College for Girls.

The seminar was attended by faculty members from the Pharmaceutical Sciences department, along with students from the master’s program in Drug Discovery and Development.

The seminar was titled: “Promising Drug Candidates for the Treatment of Polycystic Ovary Syndrome (PCOS)”.

Dr. Hanan Sayed Anbar, has a broad range of interests spanning cancer treatment, inflammation, hormonal disturbances, and endocrinal disorders. She collaborated with institutions and scholars from the USA, UK, Pakistan, the United Arab Emirates, Egypt, and the Republic of Korea.

During the seminar, Dr. Anbar delved into innovative alternatives to the traditional use of metformin for managing PCOS. Dr. Anbar introduced the therapeutic potential of several new drug candidates for the treatment of PCOS, which were developed in collaboration with her team from the University of Sharjah and the University of Oxford. She highlighted three promising compounds: Irosustat (STX64), STX140, and compound 1G. These drugs were investigated for their potential in treating letrozole-induced PCOS in female Wistar rats, offering hope as alternatives to the classical medication metformin, which has long been the standard treatment for PCOS.

The seminar concluded with a lively questions-and-answers session, during which participants explored the possibilities these new drug candidates hold for advancing PCOS treatment. This enriched the discussion, allowing both faculty and students to engage more and gain valuable insights.